Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
08/05/2026 06:49
May 8 (Reuters) - Mabion SA MABP.WA: SAID ON THURSDAY THAT THEY SIGNED A LETTER OF INTENT WITH FRENCH ODDIFACT SAS TO COOPERATE ON THE USE OF DRUG MABICONCD20 IN THE AREA OF ORPHAN DISEASES THE AIM IS TO DEVELOP AND REGISTER THE MABIONCD20 DRUG SAYS PARTIES AIM TO SIGN A BINDING COOPERATION AGREEMENT BY END-2026 Source text for Workspace: nEM67wXQsa Further company coverage: MABP.WA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys